Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a randomized controlled trial.

Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical carcinoids and atypical carcinoids (TCs and ACs)).

Patients had metastatic/unresectable, somatostatin receptor (SSTR)-positive TCs or ACs.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

Seventy-seven patients were randomized (LAN, n = 51 (TCs, n = 29; ACs, n = 22); placebo, n = 26 (TCs, n = 16; ACs, n = 10)).

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Somatostatin, so expectations could not easily colour the readings.

Being open-label, the Somatostatin study did not mask who received what.

The comparison arm used a placebo, so changes seen with Somatostatin could be set against what happens without it.

What Was Measured

The adapted primary endpoint was progression-free survival (PFS) during either phase for patients receiving LAN.

Topics PubMed links to this paper include Somatostatin, Peptides, Cyclic, Neuroendocrine Tumors, Antineoplastic Agents and Lung Neoplasms.

Author keywords: atypical carcinoid, bronchopulmonary neuroendocrine tumors, somatostatin analog and typical carcinoid.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Somatostatin and Lanreotide.

The publication is from 2024 (Endocrine-related cancer), a journal based in England.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.